Marie Moberg - Moberg Pharma CoFounder

MOB Stock  SEK 18.26  0.93  4.85%   

Insider

Marie Moberg is CoFounder of Moberg Pharma AB
Phone46 8 52 23 07 00
Webhttps://www.mobergpharma.se

Moberg Pharma Management Efficiency

The company has return on total asset (ROA) of (0.0249) % which means that it has lost $0.0249 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0325) %, meaning that it generated substantial loss on money invested by shareholders. Moberg Pharma's management efficiency ratios could be used to measure how well Moberg Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
Moberg Pharma AB has accumulated 16.25 M in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Moberg Pharma AB has a current ratio of 10.45, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Moberg Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Moberg Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Moberg Pharma AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Moberg to invest in growth at high rates of return. When we think about Moberg Pharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Karin PetersonClinical Laserthermia Systems
N/A
Raquel ToscaSwedencare publ AB
49
MalineEducation Albert AB
N/A
Fredrik SatterstromMekonomen AB
N/A
Marie MScClinical Laserthermia Systems
44
Ehsan YazdanieEducation Albert AB
41
Sven KristensenMekonomen AB
N/A
Piotr ZyskMekonomen AB
N/A
LarsErik ErikssonClinical Laserthermia Systems
74
Marina NorbergLipum AB
59
Mikael BlomqvistKABE Group AB
42
Stein YndestadNorva24 Group AB
55
Stefan OlssonEnzymatica publ AB
53
Jonas MartenssoneEducation Albert AB
39
Associate LindquistLipum AB
63
Bertolt GartnerNorva24 Group AB
56
Martin DahlgreneEducation Albert AB
30
Jenny GraflindSwedencare publ AB
47
Kajsa LernestaleEducation Albert AB
36
Tim NormannNorva24 Group AB
59
Anders VallenljordIAR Systems Group
55
Moberg Pharma AB , a pharmaceutical company, develops and commercializes medical products for pain and skin conditions in Europe, the United States, and internationally. Moberg Pharma AB was incorporated in 2006 and is headquartered in Bromma, Sweden. Moberg Pharma operates under Drug ManufacturersSpecialty Generic classification in Sweden and is traded on Stockholm Stock Exchange. It employs 11 people. Moberg Pharma AB (MOB) is traded on Stockholm Exchange in Sweden and employs 7 people.

Management Performance

Moberg Pharma AB Leadership Team

Elected by the shareholders, the Moberg Pharma's board of directors comprises two types of representatives: Moberg Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Moberg. The board's role is to monitor Moberg Pharma's management team and ensure that shareholders' interests are well served. Moberg Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Moberg Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Mark Beveridge, VP Fin
Anders Broijersen, Chief Officer
MSc BA, Chief Officer
Kerstin Strinnholm, Ex Chairman
Marie Moberg, CoFounder
Gunilla Wengstrm, Director Marketing

Moberg Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Moberg Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Moberg Stock Analysis

When running Moberg Pharma's price analysis, check to measure Moberg Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moberg Pharma is operating at the current time. Most of Moberg Pharma's value examination focuses on studying past and present price action to predict the probability of Moberg Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moberg Pharma's price. Additionally, you may evaluate how the addition of Moberg Pharma to your portfolios can decrease your overall portfolio volatility.